Redeye: Carasent prel. Q2 - Soft Q2 causing revised 2025 targets – largely aligning with our unrevised forecasts
Redeye comments on Carasent’s preliminary Q2 figures, the revised 2025 targets, and the new mid-term targets.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/